XOMA (NASDAQ: XOMA) reported Q1 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $2.65 million versus the consensus estimate of $4.31 million.

2015 Guidance

The Company expects to spend approximately $60 million to $65 million in cash for ongoing operating activities during 2015. The Company's principal expenditures are costs associated with its gevokizumab Phase 3 clinical programs. The guidance assumes license and contract-related revenue to be received during the course of the year.

For earnings history and earnings-related data on XOMA (XOMA) click here.